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Abstract
Background: Randomized controlled trials can be expensive and time-consuming, leading to medical researchers
utilizing real-world evidence (RWE) based on already-collected data. We aimed to conduct various RWE studies on
angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blocker (ARB), commonly used as first-
line therapy for blood pressure, and to develop a multi-center clinical data mart (CDM) of ACEI/ARB for various
clinical purposes.
Methods: Data from electronic medical records of St. Mary’s Hospital and the Seoul National University Hospital
were collected. We obtained blood and urine test results of patients within the 30 days prior to their first prescription
of ACEI or ARB, as well as the first date of diagnosis and presence of various chronic and cardiovascular diseases using
the International Classification of Diseases-10 classification. One researcher managed data quality and collation for each
hospital in order to facilitate patient anonymity. When results were unclear, the responsible investigator for each
hospital attempted to resolve ambiguities by direct chart review.
Results: A total of 102,333 patients who were prescribed ACEI or ARB for the first time were included (21,481 ACEI,
80,551 ARB, and 301 both). Our ACEI/ARB-CDM included short-term studies (within 12months) to observe changes
in various blood or urinary laboratory test values after the initial prescription of ACEI or ARB and long-term studies to
confirm the incidence of various diseases.
Conclusion: We established a CDM of RWE for ACEI/ARB prescription, which included various clinical studies. As we
accumulate experience in this process, we expect that the use of RWE research will grow and develop.
Keywords: Angiotensin-converting enzyme inhibitors (ACEI), Angiotensin II receptor blocker (ARB), Clinical data mart
CDM), Real world data (RWD), Real world evidence (RWE)
Background
“Big data” as an analysis tool has become a recognized
part of medical research. In 2011, McKinsey Global Insti-
tute [1] defined big data as datasets whose size is beyond
the ability of typical database software tools to capture,
store, manage, and analyze. The phrase “big data,” used
primarily in the information and communications tech-
nologies (ICT) field, has been modified to the phrase “real
world data” (RWD) for use in the medical community.
RWD is not limited to data from traditional clinical
research, and includes data generated from patients’ life-
styles as well as medical information [2, 3]. The U.S. Food
and Drug Administration (FDA) [4] defines RWD as data
relating to patient health status and/or the delivery of
health care routinely collected from a variety of
sources and clinical research, for use as real-world
evidence (RWE).
Medical researchers are interested in RWE using data
already accumulated since randomized controlled trials
(RCT) are expensive and time-consuming [5]. The four
major medical RWD types include electronic medical
record (EMR) data used in hospitals, genomic data, pub-
lic information data, and lifelog data. Among the four
RWDs, the most refined and structured EMR data is
recognized as the most reliable data and is comparatively
easily accessible. There are disadvantages in that it can
* Correspondence: 01cadiz@hanmail.net; juhan@snu.ac.kr
1Department of Medical Informatics, College of Medicine, The Catholic University
of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, Republic of Korea
3Division of Biomedical Informatics, Systems Biomedical Informatics Research
Centre, Seoul National University College of Medicine, 103 Daehak-ro,
Jongno-gu, Seoul 110-799, Republic of Korea
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kim et al. Clinical Hypertension           (2018) 24:18 
https://doi.org/10.1186/s40885-018-0103-7
be difficult to analyze unstructured data such as free-
hand text-based notes, but clearly structured data such
as imaging data, video, and quantitative laboratory data
can also be used [6].
Many medical researchers are attempting RWE studies
using EMR data [7–10]. However, if the research hy-
potheses and design are not clearly defined prior to the
beginning of the study, RWE is prone to serious errors
or bias, and the results are often unreliable. Data quan-
tity cannot override the importance of ensuring adequate
and unbiased control and analysis, and poorly built data-
sets can be configured based on intrinsically biased de-
signs. We aimed to gather various RWE on the use of
angiotensin-converting enzyme inhibitors (ACEI) and
angiotensin II receptor blockers (ARB), commonly used
as first-line therapy for hypertension [11–13], by build-
ing a multi-center clinical data mart (CDM) on ACEI/
ARB. The process used to develop this CDM is intended
to assist researchers who wish to develop similar clinical
data marts for RWE purposes.
Methods
Privacy protection and IRB
St. Mary’s Hospital and the Seoul National University
Hospital participated in this retrospective cohort study.
Data stored in EMRs were used. Because the patients had
already been treated, the study did not directly affect the
patients. Data on personal information were stored in an
encrypted database at each hospital and were accessible
only to a designated responsible investigator. Owing to
the anonymity of the data and the retrospective nature of
the study, informed consent was not required. Patient in-
formation was stored after deleting the identifying regis-
tration numbers and replacing them with a temporary
identifier; the files matching the temporary registration
numbers were also encrypted and stored separately. These
temporary numbers were accessible only to the respon-
sible investigator at each hospital, who was blinded to pa-
tient information outside the designated hospital
jurisdiction. The temporary patient numbers were only
used when the data were required for integration during
statistical analyses. If individual chart reviews of the pa-
tients were required, they were requested through the
temporary number from the responsible investigator at
each hospital, and the registration numbers of the patients
were deleted prior to providing the data. This study was
approved by the institutional review boards (IRB) of the
Catholic University of Korea and the Seoul National
University Hospital.
Definition of EMR extraction by ACEI or ARB
ACEI medication prescribed in the Seoul St. Mary’s Hos-
pital and the Seoul National University Hospital con-
sisted of eight types: Captopril (12.5 mg, 25 mg, or 50
mg), Enalapril (5 mg or 10mg), Ramipril (2.5 mg, 5 mg,
or 10 mg), Lisinopril (10 mg), Imidapril (5 mg or 10 mg),
Moexipril (7.5 mg or 15mg), Perindopril (4 mg or 8 mg),
and Zofenopril (7.5 mg, 15 mg, or 30 mg). ARB was
prescribed as seven types, including Candesartan (8 mg,
16 mg, or 32 mg), Valsartan (80 mg or 160 mg), Fimasar-
tan (30 mg, 60 mg, or 120 mg), Irbesartan (150 mg or
300 mg), Olmesartan (10 mg, 20 mg, or 40 mg), Telmi-
sartan (40 mg or 80mg), and Eprosartan (600 mg).
Patient data records were selected on the basis of receiv-
ing their first prescriptions of ACEI or ARB. Based on
these records, we extracted information including date of
birth, height, weight, and systolic and diastolic blood pres-
sure at the time of first prescription. We also extracted
hospital information such as the department that first pre-
scribed ACEI or ARB, the last prescribing department, the
number of prescription days, and hospitalization status.
Blood test and urine test results for blood urea nitrogen
(BUN), creatinine, sodium, potassium, uric acid, and other
values from within 30 days prior to ACEI or ARB prescrip-
tion were recorded. If there were more than two test re-
sults within the above period, we extracted ACEI or ARB
to a value close to the date on which it was first prescribed.
We further extracted the first date of diagnosis as well as
presence of various chronic and/or cardiovascular diseases
[14]. We were able to determine whether the onset of each
patient’s disease occurred before or after the first prescrip-
tion of ACEI or ARB and calculate how many days later
the disease recurred. If a diagnosis date was earlier based
on the date that the ACEI/ARB was first prescribed, it was
included as already diagnosed baseline characteristics. If
ACEI or ARB was diagnosed after the date of first pre-
scription, it was defined as the incidence of each disease
following the use of ACEI/ARB. The diagnostic name of
the extracted disease was assigned using the International
Classification of Diseases (ICD)-10 classification, which in-
cluded hypertensive diseases (I10–15), ischemic heart dis-
eases (I20–25), cerebrovascular diseases (I60–69),
aneurysm dissection (I71–73), diabetes mellitus (E10–15),
cancer (C-), osteoporosis (M80–82), heart failure (I50,
I11.0, I13.0, I24.8), and acute renal failure (N179).
Information on specific prescriptions in addition to
ACEI/ARB was also extracted, including date of initial
prescription and date of last prescription, and the drug
was configured to check whether or not a drug was ad-
ministered during each study period. Types of medications
included β-blockers, calcium channel blockers, diuretics,
non-steroidal anti-inflammatory drugs (NSAIDs), and
HMG-CoA reductase inhibitors.
Design
Our ACEI/ARB-CDM was designed as short-term stud-
ies of 12-month duration to observe changes in various
test values such as microalbuminuria or hyperuricemia
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after the initial prescription of ACEI or ARB, as well as
long-term studies to confirm the incidence of various
disease (Fig. 1). In contrast with RCT, RWE makes it dif-
ficult to accurately predict hospital visits, and actual visit
dates are very diverse. For this reason, in this study, the
date when a patient was first prescribed ACE was de-
fined as “visit 0.” A subsequent visit 45–136 days later
(with a mean of 90 days) was defined as “visit 1”. A sub-
sequent visit 137–227 days later (mean 180 days) was de-
fined as “visit 2,” a visit 228–318 days later (mean 280
days) was defined as “visit 3,” and a visit 319–410 days
later (mean 365 days) was defined as “visit 4.” For each
visit, information regarding the above measures, pre-
scription changes in ACEI or ARB, and blood and urine
test items were collected.
Data quality management
Data quality management (DQM) is essential for data
extracted for EMR-based clinical research prior to statis-
tical analysis. DQM must be performed continuously in
order for the extracted data to be used suitable for pur-
pose. In our study, quality control of data values and
data structure were simultaneously managed. DQM was
conducted by one researcher after integrating data from
each hospital. Unstructured laboratory data including
characters such as “> 3” and “3+” were deleted, and cases
where data management software could not recognize
input due to punctuation error were corrected manually.
Quality control methods were stored in a standard for-
mat for integrating data from the two hospitals into a
single dataset. Records of modified data were recorded
and the original files were saved separately.
Direct chart review
In case of DQM of specific data values, such as in un-
structured laboratory data containing characters or test
results that were not unclear with the patient’s registra-
tion number, the responsible investigator at each hos-
pital attempted to directly modify records by reviewing
patient charts.
Results
Between January 1, 2009 and December 31, 2017, a total
of 102,333 patients were first prescribed ACEI or ARB at
the Seoul St. Mary’s Hospital and the Seoul National
University Hospital. This dataset included 56,262 men
(55.0%) and 46,069 women (45.0%), as well as two for-
eign nationals whose gender could not be identified
based on chart review. The mean age was 59 ± 28 years,
with 31,197 patients (30.5%) being over 70 years old,
27,301 patients (26.7%) in their 60s, 21,038 patients
(20.6%) in their 50s, and 10,079 patients (9.8%) in their
40s (Fig. 2a). In 33,455 cases (32.7%), ACEI/ARB was re-
ported by a cardiology department, in 10,921 cases
(10.7%) by a nephrology department, in 9380 cases
(9.2%) by an endocrinology department, and in 9275
cases (9.1%) by a neurology department. (Fig. 2b).
ACEI was first prescribed in 21,481 cases (21.0%) and
ARB was first prescribed in 80,551 cases (78.7%). In 301
cases (0.3%), ACEI and ARB were prescribed at the same
time (Fig. 2c). Of the 21,481 patients prescribed ACEI,
Enalapril was prescribed to 41.8% (8974/21,481 patients),
Ramipril was prescribed to 30.8% (6609/21,481 patients),
Perindopril was prescribed to 11.1% (2391/21,481 patients),
Captopril was prescribed to 9.8% (2107/21,481 patients),
Imidapril was prescribed to 4.0% (858/21,481 patients),
and Lisinopril was prescribed to 1.3% (279/21,481 pa-
tients). For the 80,551 patients prescribed ARB, 25.0%
(20,105/80,551 patients) received Candesartan, 19.6%
(15,768/80,551 patients) received Valsartan, 15.2% (12,272/
80,551 patients) received Telmisartan, 11.6% (9334/80,551
patients) received Irbesartan, 12.3% (9907/80,551 patients)
received Olmesartan, and 10.9% (8776/80,551 patients) re-
ceived Fimasartan.
A total of 1.3% (1297 /102,333 patients) had been diag-
nosed with heart failure prior to first prescription of ACEI
or ARB and 0.9% (889/102,333 patients) were diagnosed
after first prescription. Acute myocardial infarction had
previously occurred in 2.2% (2252/102,333 patients)
and occurred in 1.0% (1050/102,333 patients) subse-
quently. Angina pectoris had previously occurred in 8.8%
(9050/102,333 patients) and 4.2% (4266/102,333 patients)
were diagnosed subsequently. In the case of ischemic























No ACEi or ARB ACEi or ARB prescription
Fig. 1 Design of ACEI/ARB-clinical data mart. ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blocker
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heart disease, including angina and acute myocardial in-
farction, 12.1% (12,409/102,333 patients) were diagnosed
before first ACEI/ARB prescription and 5.1% (5179/
102,333 patients) were diagnosed subsequently. Cerebro-
vascular disease, including stroke, was diagnosed in 10.0%
(10,191/102,333 patients) before the first prescription and
in 3.8% (3877/102,333 patients) after the first prescription.
Aneurysm dissection already had previously occurred in
0.9% (931/102,333 patients) and 0.7% (672/102,333 pa-
tients) were diagnosed subsequently. Diabetes mellitus was
present in 3.9% (3975/102,333 patients) at first prescription
and 2.3% (2279/102,333 patients) subsequently. Gout was
present in 0.2% (215/102,333 patients) and later diagnosed
in 0.4% (431/102,333 patients). Erectile dysfunction had
previously occurred in 0.02% (26/102,333 patients) and
occurred later in 0.1% (98 /102,333 patients). Cancer had
been diagnosed in 8.3% (8463/102,333 patients) and 3.6%
(3666/102,333 patients) were diagnosed subsequently.
Renal failure had occurred in 0.1% (127/102,333 patients)
and 0.2% (180 /102,333 patients) were diagnosed later. Sud-
den cardiac death occurred in 0.2% (180 /102,333 patients)
after their first prescription of ACEI/ARB.
There were 25,753 patients (25.2%) who were prescribed
β-blockers, 35,927 (35.1%) prescribed statin drugs, 36,161
(35.3%) prescribed CCB, 30,339 (29.6%) prescribed di-
uretics, and 6461 (6.3%) prescribed K-sparing diuretics.
Discussion
The establishment of CDM enables numerous clinical
studies with a single construction [15]. We have estab-
lished a CDM for ACEI/ARB, which includes patient
basic data, test data, and diagnosis name. A variety of
clinical research is in progress to utilize it.
In cases where a CDM needs to be built for research
purposes, baseline characteristics such as systolic blood
pressure, diastolic blood pressure, height, and weight
that medical staff enter into the EMR manually are ex-
tremely important. Data regarding baseline characteris-
tics obtained for this study were not satisfactory, due to
numerous missing or incorrectly entered data. In build-
ing CDMs, clinical researchers working with data may
feel intuitively that a value was entered incorrectly, but
it is not permissible to arbitrarily modify it. In some of
these instances, a guide or protocol is required to iden-
tify incidents where height or weight are reversed or in-
correctly entered; in such cases, when the protocol itself
is not clearly presented, it can act as an error from the
start of the study if this process is shaken. Ideally, data
directly entered by medical staff should only be cor-
rected by the staff member in question during the chart
review process. However, the biggest strength of the
EMR-based research over RCT is that data can be ex-




Fig. 2 Analysis of ACEI/ARB-clinical data mart (n = 102,333) (a) age, (b) department, (c) type of ACEI or ARB. ACEI, angiotensin-converting enzyme
inhibitors; ARB, angiotensin II receptor blocker
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frequent chart reviews are made. Moreover, it is virtually
impossible to review chart data piece by piece if there are
more than a few thousand large CDM deployed. All told,
for effective CDM building, large numbers of patients
must be included, making human error nearly inevitable
and predisposing studies to bias. This emphasizes the im-
portance of advance anticipation of such issues and the es-
tablishment of written protocols and guidance prior to the
commencement of clinical research.
The most clear and reliable data points in EMR data-
bases come from blood testing [16], with such structured
objective data tending to have fewer errors. Moreover,
since the normal range of test results is clearly defined,
most RWE studies rely on laboratory data [16–18]. This is
the most reliable data for estimating incidence of adverse
drug reactions [19–21]. However, it is necessary to define
missing data that are outside of the measurable range of
equipment. These may be reported as “< 0.3” or “higher
than 18,” or may be entered as missing data. As before, it
is important to establish clear protocols for dealing with
these instances prior to research and a significant amount
of data loss may be inevitable [22]. This may also require
manual work through direct chart review.
The next most clear and structured form of data are
the specific diagnoses for diseases. ICD-9 or ICD-10
classification is suitable for this purpose. For example, it
is possible to extrapolate the correlation between a spe-
cific drug and a specific diagnosis in order to determine
whether a specific diagnosis occurred before or after the
drug is administered. In addition, it is possible to calcu-
late the interval from the first administration of a spe-
cific drug to the first date that a specific disease was
diagnosed. For example, it is straightforward to conduct
studies into the difference in the incidence of diabetes
according to the prescription of statin, a dyslipidemia
drug [23]. Here again, the biggest hurdle is omitted diag-
nosis by the medical staff. There may be a difference be-
tween a patient’s actual diagnosis and the diagnostic
name (billing or claiming data) that medical staff enter
manually. In practice, medical staff are often passive in
adding new diagnostic names [24]. Severe concerns such
as cancer and myocardial infarction tend to have a
clearer diagnosis, but milder concerns such as common
cold, nausea, or constipation are more likely to be omit-
ted and unreliable. As such, researchers should be aware
of the potential for underestimation when conducting
studies of specific diagnostic nomenclature.
RWE studies are the most advantageous to evaluate side
effects with low incidences [25], as side effects with lower
incidence are less likely to be observed in RCTs but can
be easily identified within a large CDM of patients who
have already been treated. Using our CDM, we conducted
a study on ARB-related angioedema with a low incidence
of expression [26], which indicated that it is significantly
overlooked by medical staff. In fact, if it is a side effect
from the experience of the medical staff, not from the side
effects of the examination or clear structured laboratory
data, follow-up research may be difficult due to incom-
plete chart records. This is why many studies have been
conducted on data standards recently.
The data mart built in this study includes data on all
patients who were first prescribed ACEI/ARB. There
was no manipulation of data, except for that described
in the Methods section. The Reviewer is well aware of
the manipulation and the fact that it was inevitable due
to missing data for each item (because of the differences
in the tendency of the physician to record data and the
characteristics of each division). For example, in this
study, the missing data for BMI were as high as 55.7%
(56,981/102,333), because BMI data had to be entered
manually. In contrast, missing data on laboratory blood
tests were low because of the structured nature of the
data. Nevertheless, for laboratory blood test data, the
distribution of missing data varied for each test item, ac-
cording to the characteristics of each division or phys-
ician. If researchers want to conduct studies related to
ACEI/ARB, they can use this data mart, and depending
on the purpose of the study, each item that they want to
extract within the same data mart will be different. The
researcher should be clearly aware of this before pro-
ceeding with the study. In other words, the data required
from the data mart will vary depending on the purpose
of the study. Therefore, even if there are missing data
while building a data mart, manipulation or supplemen-
tation by selection, exclusion, addition, and deformation
should not be performed. Researchers should be aware
of the missing data already and choose appropriately to
meet the purpose and hypothesis of their studies.
Our team has conducted several studies on RWE and
has built various CDMs [8, 15, 19, 26], but many meth-
odological errors remain to be corrected. In many existing
RWEs, it is often the case that a large sample size offers
an appealing advantage over RCTs. However, unlike RCTs,
which aim for group homogeneity, RWDs do not provide
a lot of information due the heterogeneity of the included
patient data [27]. An important aspect to be addressed in
the future is the need for standardized protocols, mainly
in terms of data extraction: data should exist in a
well-structured form and should be easy to extract. How-
ever, the current EMR system unfortunately does not
meet these needs. Therefore, in order to extract the cor-
rect data without missing data in the future, standardized
protocols for input and preparation, standardized by re-
searchers, clinics, and hospitals, will be needed. In other
words, to eliminate missing data, the data should be col-
lected in a structured format for easy entry. Second, from
the standpoint of medical staff utilizing extracted data,
standardized protocols for data utilization are required.
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This is because, depending on how researchers utilize
their data (or depending on the statistical approach), it
may lead to varying results. These two aspects mentioned
above are also the limitations of RWE, which have to be
overcome and will not be easy, because EMR data are not
intended for clinical research and for use to develop data
marts. Several concerns remain regarding data collection
to develop data marts, as this area of research is still in the
developmental stage. Nevertheless, it is natural that we
should strive to minimize missing data, and it is possible
to minimize biases only by conducting research using
stringent and well-designed protocols.
Conclusions
RWE is already recognized as a novel clinical research
method, and its influence is enormous. However, it does
not challenge to the strengths of RCT, and instead may be
valued as a study preceding RCT. RCTand RWE are com-
plementary and we expect that their use in conjunction
can compensate for the disadvantages of conventional
RCT. Nonetheless, even using large sample sizes, there
are many questions that cannot be answered with confi-
dence and will need to be continually attempted and sup-
plemented. In this study, we have established a CDM for
RWE regarding ACEI/ARB therapy and expect various
clinical studies to be available accordingly. As we accumu-
late experience in this process, we expect that much of
RWE research will grow and develop.
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